J&J drops its option on Provention Bio drug after trial failure
Two months after a mid-stage flop, J&J told Provention Bio they weren’t going to buy back a Crohn’s disease drug.
J&J licensed the molecule …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
